Integrative Metabolism Program

Integrative Metabolism Program

Fundamental and translational research in metabolism can help solve obesity-related diabetes and its complications.


When metabolism goes awry we become at risk of metabolic syndrome—a  group of risk factors that include obesity, high blood pressure, and elevated glucose and cholesterol levels that increase risk of heart disease and diabetes. We are working to understand how signaling networks integrate with gene regulation to influence metabolic disease.

What is the focus of our program?

The program investigates how organs and cells work together to respond to biological and environmental challenges that influence the development and progression of metabolic diseases such as cardiovascular disease, obesity, and type 2 diabetes. There is significant focus on how signaling pathways and gene regulatory mechanisms maintain metabolic homeostasis and on genetic, epigenetic or environmental mechanisms that contribute to complications in the processing of nutrients for energy utilization and storage that are present in metabolic syndrome. Another important area of study is how insulin resistance and diabetes develop in states of caloric excess through the pathologic “crosstalk” across a variety of cells and tissues.

How will our research help patients?

Our research helps to decipher the fundamental cellular defects associated with metabolic diseases and how individual molecular defects combine to influence outward disease phenotypes. Through robust collaborations with our clinical partners at the Florida Hospital - SBP Translational Research Institute for Metabolism and Diabetes and others, discoveries emerging from our laboratories are rapidly translated into focused clinical studies that examine their relevance to human health. Because metabolic changes are also fundamental to many other pathological conditions, ranging from Alzheimer's disease to cancer, the basic principles of our research will also provide insight and therapeutic avenues for combating other major human diseases.


Program Director Timothy Osborne, Ph.D.
Primary Appointments
Adjunct Appointments Paul Coen, Ph.D.


Pratley RE
Diabetes Technol Ther 2016 Nov;18(11):671-673
Pino MF, Parsons SA, Smith SR, Sparks LM
Obesity (Silver Spring) 2016 Dec;24(12):2467-2470
Khorasanizadeh S, Rastinejad F
Endocrinology 2016 Nov;157(11):4212-4221